Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology
ACS Nano · 2025
DOI: 10.1021/acsnano.3c12532 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Huei-Han Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, National Cheng Kung University, Tainan 70101, Taiwan. Hauptthemen laut MEDLINE: Acute Lung Injury, Fingolimod Hydrochloride, Antioxidants, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Medical University Hospital, China Medical University, National Cheng Kung University.
Abstract (Originalsprache)
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), a rapidly progressing respiratory failure condition, results in a high mortality rate, especially in severe cases. Numerous trials have investigated various pharmacotherapy approaches, but their effectiveness remains uncertain. Here, we present an inhaled nanoformulation of fingolimod (FTY720)-nobiletin (NOB)- poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) with good biocompatibility and a sustained-release pharmacological effect. The formulation decreases the toxicity of FTY720 and increases the bioavailability of NOB since we use PLGA with a high biocompatibility to encapsulate FTY720 and NOB at the same time. In vitro, in comparison to treatment with the pure drug, we demonstrated that FTY720-NOB-PLGA NPs can reduce interleukin-6 (IL-6) and reactive oxygen species (ROS) release by macrophages after lipopolysaccharide (LPS) stimulation more efficiently. In vivo, we used an inhalation tower system that allowed the exposure of unanesthetized mice to aerosolized FTY720-NOB-PLGA NPs under controlled conditions. We demonstrated that inhaled FTY720-NOB-PLGA NPs can attenuate lung injury after LPS exposure by suppressing cytokine release, such as IL-6 and tumor necrosis factor-α (TNF-α). The trigger pathway of ALI, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and p38 mitogen-activated protein kinase, was also efficiently inhibited. Furthermore, the inhalation treatment provided a good safety profile, without detrimental effects on biochemical markers and lung function. We provided the feasibility of administering inhalation of NPs noninvasively with continuous monitoring of lung function. The aerosolized FTY720-NOB-PLGA NPs we developed show excellent promise for acute lung injury therapy in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, National Cheng Kung University, Tainan 70101, Taiwan.
- Center for Allergy Immunology and Microbiome (AIM), China Medical University Children's Hospital/China Medical University Hospital, China Medical University, Taichung 404327, Taiwan.
- Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
- Medical Imaging Center, Innovation Headquarters, National Cheng Kung University, Tainan 70101, Taiwan.
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
ORCID-Profile: Huei-Han Zhang, Min-Hsiung Pan, Chien-Chung Lin
Förderung
- China Medical University Hospital
- China Medical University
- National Cheng Kung University
- National Science and Technology Council
- Ministry of Education, Taiwan
Zitieren
APA
Zhang, H. H., Kuo, W. S., Tu, P. Y., Lee, C. T., Wang, H. C., Huang, Y. T., Shen, M. C., Lin, T. S., Su, P. L., Tsai, J. S., Pan, M. H., Lin, C. C., & Wu, P. C. (2025). Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology. ACS Nano. https://doi.org/10.1021/acsnano.3c12532
Vancouver
Zhang HH, Kuo WS, Tu PY, Lee CT, Wang HC, Huang YT, et al. Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology. ACS Nano. 2025. doi:10.1021/acsnano.3c12532
BibTeX
@article{Zhang2025,
author = {Zhang, Huei-Han and Kuo, Wen-Shuo and Tu, Pei-Yu and Lee, Chung-Ta and Wang, Hao-Chen and Huang, Yu-Ting and Shen, Mei-Chun and Lin, Tsai-Shiuan and Su, Po-Lan and Tsai, Jeng-Shiuan and Pan, Min-Hsiung and Lin, Chien-Chung and Wu, Ping-Ching},
title = {Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.3c12532}
}
EUVIMED